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Abstract
Background: Central nervous system tumours constitute 25% of all childhood cancers; more than half are located
in the posterior fossa and surgery is usually part of therapy. One of the most disabling late effects of posterior fossa
tumour surgery is the cerebellar mutism syndrome (CMS) which has been reported in up to 39% of the patients but
the exact incidence is uncertain since milder cases may be unrecognized. Recovery is usually incomplete. Reported risk
factors are tumour type, midline location and brainstem involvement, but the exact aetiology, surgical and other risk
factors, the clinical course and strategies for prevention and treatment are yet to be determined.
Methods: This observational, prospective, multicentre study will include 500 children with posterior fossa tumours. It
opened late 2014 with participation from 20 Nordic and Baltic centres. From 2016, five British centres and four Dutch
centres will join with a total annual accrual of 130 patients. Three other major European centres are invited to join from
2016/17. Follow-up will run for 12 months after inclusion of the last patient. All patients are treated according to local
practice. Clinical data are collected through standardized online registration at pre-determined time points pre- and
postoperatively. Neurological status and speech functions are examined pre-operatively and postoperatively at 1–4 weeks, 2
and 12 months. Pre- and postoperative speech samples are recorded and analysed. Imaging will be reviewed centrally.
Pathology is classified according to the 2007 WHO system. Germline DNA will be collected from all patients for associations
between CMS characteristics and host genome variants including pathway profiles.
Discussion: Through prospective and detailed collection of information on 1) differences in incidence and clinical course
of CMS for different patient and tumour characteristics, 2) standardized surgical data and their association with
CMS, 3) diversities and results of other therapeutic interventions, and 4) the role of host genome variants, we aim
to achieve a better understanding of risk factors for and the clinical course of CMS - with the ultimate goal of defining
strategies for prevention and treatment of this severely disabling condition.
Trial registration: Clinicaltrials.gov: NCT02300766, date of registration: November 21, 2014.
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Background
Incidence and definition of CMS
Central nervous system (CNS) tumours account for 25%
of all cancers in children and over half of these are located
in the posterior fossa [1]. For most of these patients, treat-
ment includes surgery. Posterior fossa tumours in children
are associated with high risk of chronic neurological and
neurocognitive disability [2–6]. The cerebellar mutism
syndrome (CMS) refers to the constellation of transient
mutism, ataxia, hypotonia and irritability following surgery
for cerebellar or fourth ventricle tumours in children and
adolescents [7]. Although some patients may recover
completely, recovery may be prolonged, and many are left
with permanent disabling sequelae in the form of e.g. dys-
arthria, dysfluency, slowed speech rate and ataxia. Many
may in addition be burdened by emotional problems and
lower IQ [8–12].
The spectrum of CMS definitions varies greatly [7, 12–14],
leading to differences in reported incidence and uncertainties
about recovery. Incidence figures thus range from 8%
[15, 16] to 32% [17] in children with any kind of cere-
bellar tumour when a variety of definitions are used,
compared to 24% [12] to 39% [18] in patients with me-
dulloblastomas using a more precise CMS definition. A
recent study of 148 children with cerebellar tumours
found that the overall incidence of the broader Posterior
Fossa Syndrome was 28%, subdivided by tumour path-
ology into 40% for medulloblastoma, 16% for astrocytoma
and 20% for ependymoma [19]. The CMS definition
created by the Neurology Committee of the Children’s
Cancer Group in USA in 1993 is currently the only one
associated with a specific scoring scale [12] and is used in
this project.
Risk factors and prevention
Cerebellar mutism is thought to be caused by bilateral
disturbance of the dentate nuclei and/or their efferents
[16, 20–24]. Ataxia and irritability together with other
cognitive, affective and motor symptoms that are fre-
quently observed in CMS patients are caused by damage
to various parts of the cerebellum and cerebello-cerebral
pathways passing through the brainstem [25–28]. This can
result in secondary diaschisis of supratentorial brain areas
due to lack of excitatory input from cerebellum [29–31].
Known risk factors are brainstem involvement by the
tumour, midline location and tumour type; thus the inci-
dence in children with medulloblastoma is two to three
times higher than for astrocytoma or ependymoma but
the biological mechanisms behind these associations are
uncertain [12, 19, 22, 32–35]. Recently proposed risk
factors include brainstem compression by the tumour,
pre-operative language impairment, low socioeconomic
level of the families and left-handedness [24, 36–38];
however, these remain to be verified on large patient
cohorts. Tumour size, neurosurgical techniques and ap-
proaches, radical resection and younger age at diagnosis
are uncertain risk factors, as previous studies have been
inconclusive [12, 23, 32–35, 39, 40]. Gender, hydrocephalus,
post-operative central nervous system infections, type
of neurosurgeon (adult/paediatric), and oedema/swell-
ing of the cerebellum have not been significantly cor-
related to CMS and are considered unlikely risk
factors [12, 16, 34, 35, 41, 42].
In traumatic brain injury common host genomic vari-
ants are related to the severity of symptoms and degree of
recovery [43–45]. Similar associations are likely for surgi-
cal brain injury, but such studies have not been performed
for CMS.
Non-surgical treatment
Supportive speech and rehabilitation therapy is often
offered to patients with CMS, but the benefit hereof has
not been demonstrated. No publications exist on system-
atic approaches to pharmacological neuroprotection, and
pharmacological interventions are only sporadically re-
ported in the literature [46–50]. Glucocorticosteroids are
routinely given to most patients pre-, intra- and post-
operatively to reduce inflammation and edema [51] [52],
but there is no consensus recommendation and the im-
pact on the clinical course of CMS is undetermined.
Aims
The study focuses on the risk factors for development
and severity of CMS including surgery (approaches,
techniques and tissue and vascular damage, re-operation)
and host genome variants. The aims of this study are thus
to describe differences in incidence, severity and clinical
course of CMS related to:
1. Clinical factors: gender, age, handedness, speech,
language and neuropsychological abilities before and
after surgery.
2. Tumour factors: histological tumour type and tumour
location
3. Surgical factors: Surgical strategy and surgical
trauma including access routes, removal technique,
tissue and vascular injury, bleeding and primary
surgery vs. re-operation
4. Non-surgical interventions: glucocorticosteroids, other
symptomatic medication and chemo- and radiotherapy
5. Host genome variants
Methods/design
Design
This open observational study is registered at Clinicaltrials.
gov (file NCT02300766) and EANS (http://www.sbns.or
g.uk/index.php/research/eu-multi-centre-trials). All children
younger than 18 years with a tumour in the posterior fossa
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requiring surgery or open biopsy at one of the participating
centres will be included following informed consent. Patients
who have received surgery, chemotherapy and/or radio-
therapy previously are also eligible. The study will run
for five years with a targeted sample size of 500 patients. It
opened late 2014 with participation from 20 Nordic and
Baltic centres. From 2016, five British centres and four
Dutch centres will join leading to an expected annual ac-
crual of 130 patients. Three other major European centres
are invited to join from 2016/17. The target of 500 pa-
tients is expected to be reached in 2018. Patients will be
followed for 12 months after inclusion of the last patient,
and the study will thus be completed during 2019.The
participating centres provide surgery and supportive care
according to local practice and register all study informa-
tion in an online database developed specifically for this
study. Consensus concerning the study aims, study design
and data registration was achieved at three international
planning meetings among the initiating centres during
2013. The annual enrolment from each country will be
compared to the number of registered patients in the
national cancer registries to document the inclusion rate
and representativeness.
Primary endpoint
The primary endpoint is incidence and severity of CMS.
Symptoms and severity are scored according to the CMS
survey published by Robertsons et al. [12]. Our main
focus is the impact of different surgical tumour approaches.
We hypothesize that 1) minimally traumatic techniques
and 2) sparing the dentate nuclei and their efferents will be
associated with a 50% reduced risk of CMS when compared
to more invasive tumour removal approaches. Furthermore,
we hypothesize that the risk of developing CMS is higher
after re-operation(s) compared to primary surgery.
Secondary endpoint
The secondary endpoint is incidence of “reduced speech
output” defined as “severely reduced speech production
limited to single words or short sentences which can
only be elicited after vigorous stimulation” [19]. The risk
of reduced speech output will be related to different
surgical approaches with the underlying hypothesis that
damage to the dentate nuclei and/or their efferents in-
creases the risk.
Furthermore, we want to explore the following:
Genetics
We will analyse the role of host genome variants on de-
velopment, severity and recovery from CMS by carrying
out broad genetic pathway profiling of all study partici-
pants using both non-CMS cases from the study cohort
and non-CNS tumour patients as controls. Genotyping
will use single nucleotide polymorphism (SNP) exome
enriched arrays (e.g. Illumina Omni2.5-exome platform).
We will apply agnostic genome-wide association studies
(GWAS) as well as more complex pathway analyses.
Thus, we will interrogate combined effects of multiple
SNPs acting in the same pathways or protein-protein
interaction complexes using our validated non-linear
machine learning algorithm (artificial neural networks
approach) [53, 54], which allows testing of a large range
of pathways from various databases. This approach will
yield hypotheses easier to test across cohorts and also
provide mechanistic insights. We hypothesize that host
genome variants explain at least 50% of the variation
in incidence of CMS and at least 40% of the variation
in severity, duration and level of recovery from the
CMS.
Other non-surgical treatments including glucocorticosteroids
The possible effects of chemo- and radiotherapy on re-
covery from CMS will be investigated. We hypothesize
that chemo- and radiotherapy delay recovery from CMS.
For descriptive documentation purposes we also ask for
information on medications given specifically to treat
the symptoms of CMS.
We hypothesize that glucocorticosteroids 1) given pre-
operatively protect against CMS due to reduced oedema;
2) given intraoperatively increase the risk of CMS due to
worsening of acute neurological injury by hyperglycaemia;
3) given postoperatively negatively affect the course of
CMS as earlier studies have shown a negative effect of
glucocorticosteroids on the outcome of traumatic brain
injury [55, 56]. It may be expected that most patients re-
ceive glucocorticosteroids at all 3 time points which would
make it difficult to assess added positive and negative
effect in the same patients.
Tumour type
The incidence of the CMS will be correlated to
tumour histology using the 2007 WHO classification.
We hypothesize that the risk of CMS is highest among
patients with medulloblastoma. With increasing focus
on subtyping of medulloblastoma [57] this additional
classification may later be added to the risk factor
analysis.
Neuroradiology
Tumour location, enhancement pattern, invasiveness and
growth velocity may affect the risk and severity of CMS
[12, 18, 58]. Accordingly, we hypothesize that a statistical
risk of CMS may be predicted by defining specific neuro-
radiological features [59–61]. Likewise, postoperative neu-
roradiological features could give prognostic information
about probable degree of recovery.
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Handedness
We will determine whether the risk of the CMS varies
according to handedness. We hypothesize that the risk
of CMS is increased in left-handed patients, and possibly
even more so in patients with medulloblastoma [24].
Language and speech
Our hypothesis that preoperative speech and language
impairment increases the risk of postoperative speech
and language deficits will be explored by recording
pre- and postoperative speech (e.g. articulation, prosodic
features and voice) and language (e.g. word finding diffi-
culties, fluency and narrative ability) statuses and relating
these to incidence and course of CMS. All speech record-
ings will be analysed nationally by speech therapists.
Registration of data
The following data will be registered at five time points
by online standard registration forms:
1. Preoperatively
Hospital, country, patient related variables such as date
of birth, handedness, comorbidities, bilingualism, gender
and date of diagnosis, medical history and preoperative
neurological status. A speech and language test will be
performed and recorded. If the patient is younger than
two years a bedside assessment of speech will be per-
formed instead of a formalized test. A two millilitre blood
sample for genetic analysis will be collected.
2. Postoperatively within 72 h of surgery
Surgery related variables such as date, patient position
during surgery, surgical approach, tumour removal method
(én bloc, piecemeal or ultrasonic aspiration), duration and
course of operation, damage to non-tumour tissue, compli-
cations, technology employed (endoscopy, neuronavigation,
electrophysiological monitoring etc.), surgeon’s estimate
of tumour resection extent and presence of preopera-
tive hydrocephalus.
3. Postoperatively within one to four weeks from surgery
Approximately one to two weeks post-operatively: neuro-
logical examination, postoperative speech and language
status including speech and language recording or bedside
assessment and medications used for treatment of CMS.
Approximately four weeks post-operatively: Development
and treatment of postoperative intracranial haematoma and
hydrocephalus, leakage of cerebrospinal fluid and need for
ventilator. These complications are usually seen earlier but
we wait until the fourth post-operative week to register
these in order to ensure no complications are missed.
4. Postoperatively two months after surgery
Neurological examination, CMS-survey, speech and
language recording or bedside assessment and any medi-
cations given to treat CMS since last registration.
5. Postoperatively twelve months after surgery
Neurological examination, speech and language status
including speech and language recording or bedside
assessment, medications given since last registration
to treat CMS, chemo- and/or radiotherapy, neuropsycho-
logical assessment(s) if performed, final neuropathological
classification of tumour, and additional neuroimaging per-
formed since the first follow-up. Copies of the neuroimag-
ing and descriptions performed pre- and postoperatively
will be collected for central review.
Acute and repeated neurosurgery
In case of emergency surgery (e.g. due to risk of incarcer-
ation or coma) information about the study and invitation
to participate can be given within seven days postopera-
tively. These patients will be included in all parts of the
study except for the recording and analysis of preoperative
speech and language status.
In cases with repeat tumour surgery during the twelve
months follow-up, the patient can re-enter the study and
start a new follow-up programme (Fig. 1, Repeated
Surgeries). A new pre-operative registration is then
performed corresponding to the re-operation. Post-operative
registrations will be performed again, and used in the ana-
lysis of risk related to first versus further surgeries. If surgery
is performed again after the twelve months follow-up period,
the patient will be re-invited to participate in the study.
Statistical considerations
In accordance with our surgical hypothesis of 50% risk
reduction by less traumatic techniques, and assuming
that 35% of the patients are operated using an approach
with a low risk of CMS (assumed to be 10%) and the
remaining 65% of patients are operated using other ap-
proaches (assumed carrying a 20% risk), a total of 450
patients have to be included to identify a 5% significance
level and 80% power. Based on a projected overall risk
of CMS of 20%, an estimated frequency of a specific
SNP of 30%, and a projected doubled risk of CMS with
this particular SNP, we will need to include a total of
343 patients to identify such a genetic predisposition at
a 5% significance level with 90% power.
Discussion
The study will be the largest prospective international
study on CMS to date, and the first one to 1) systematically
register surgery, use of steroids, standardized speech
samples and 2) to investigate the influence of host gen-
ome. Detailed information on neuroradiological features,
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tumour and patient characteristics (incl. Handedness and
pre-language impairment) will also be gathered, and may
help further elucidate the incidence and clinical course of
the syndrome for various patient and tumour types.
On-line registration compliance rates to Nordic/Baltic
multicentre trials are in general above 95% [62]. Further-
more, we will implement an automated email reminder
system at the four follow-up time points and the project
coordinator and data manager will validate all data inputs,
request clarifications and updates for unclear or missing
data, and secure that DNA of sufficient quality is received,
processed and stored for later host genome analyses.
Currently, a randomized intervention study is unrealistic
due to limited data supporting any specific neurosurgical
approach and given the diversity of tumour subtypes, lo-
calisation and invasiveness. However, such a randomisa-
tion may be realistic if the present study does not clearly
identify surgical approaches with statistically significant
reduced risks of CMS.
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